STOCKWATCH
·
Biotechnology: Laboratory Analytical Instruments
Quarterly ResultApr 29, 2026, 06:17 AM

AVTR Q1 Net Sales $1.58B; GAAP EPS $0.06; Reaffirms FY26 Guidance

AI Summary

Avantor, Inc. reported first-quarter 2026 financial results, with net sales of $1,581 million, flat compared to the prior year, though organic sales declined by 4.1%. Net income decreased to $43 million from $64.5 million in Q1 2025, and diluted GAAP EPS was $0.06. Adjusted EBITDA reached $219 million, and adjusted EPS was $0.17. The company generated $59 million in operating cash flow and $25 million in free cash flow. CEO Emmanuel Ligner noted that results exceeded expectations due to improved execution and stabilization in VWR, and the company reaffirmed its full-year 2026 guidance.

Key Highlights

  • Net sales $1,581 million (flat YoY reported, -4.1% organic).
  • Net income $43 million (down from $64.5 million in Q1 2025).
  • Diluted GAAP EPS $0.06; adjusted EPS $0.17.
  • Adjusted EBITDA $219 million.
  • VWR Distribution & Services net sales $1,150.0 million (-0.4% reported).
  • Bioscience & Medtech Products net sales $431.4 million (+1.2% reported).
  • Operating cash flow $59 million; free cash flow $25 million.
  • Reaffirmed full-year 2026 financial guidance.
AVTR
Biotechnology: Laboratory Analytical Instruments
Avantor, Inc.

Price Impact